#Spain #Barcelona #Advanced Therapies #Phacilitate

Advanced Therapies Europe 2025: Shifting Paradigms in Biotechnology

In a notable shift for the biotechnology sector, Advanced Therapies Europe is set to launch its first-ever event in the vibrant city of Barcelona, Spain, from September 2 to 4, 2025. This year’s edition focuses on a daring new format, intentionally designed to create immersive experiences limited to just 500 participants. This restriction emphasizes the importance of meaningful interactions and aims to accelerate innovations in the field of cellular and gene therapies.

The event, hosted at the prestigious Hotel Arts, Ritz-Carlton, is strategically located in one of Europe’s most dynamic biotechnology hubs. Attendees will include leaders from biotech and pharmaceutical companies, investors, regulators, academics, solution providers, and manufacturing experts, coming together for three days packed with valuable content, strategic networking, and targeted deal-making.

Discussions will cover pressing industry topics, such as investment trends, market strategies, clinical development, commercialization, emerging technologies, and the evolving regulatory landscape globally. The event’s agenda features a variety of formats—including in-depth workshops, interactive sessions, and roundtable discussions—all designed to foster open dialogue and collaborative problem-solving.

This year's confirmed speakers represent a powerhouse of knowledge and experience within the industry. Attendees will hear insights from leaders like Miguel Forte, CEO of Kiji Therapeutics; Thomas Carlsen, CEO of Novo Nordisk Cellerator; Ase Rosenqvist from Johnson & Johnson’s Nordic cell therapy business unit; Eleuterio Lombardo, Director of Cell Therapy Characterization at Takeda; and Angela Vollstedt, Global Head of Cell and Gene Therapy Portfolio at Novartis.

Additionally, the event will once again host two key summits focusing on women in advanced therapies and investment strategies. These summits will provide dedicated spaces for mentorship, innovation, and strategic alignment, ensuring that offerings are tailored to the unique challenges and opportunities within the sector. A renewed innovation showcase will spotlight groundbreaking biotechnology firms and directly connect them with investors eager to shape the future of the industry.

Ingerid Sorgaard, the content director at Phacilitate, emphasizes the newly designed event as being more dynamic and interaction-oriented. "It's not merely about delivering content, but also about fostering the right conversations in the optimal context," Sorgaard notes. From roundtables and in-depth workshops to rooftop networking and interactive formats, every aspect aims to spark significant connections, encourage fresh ideas, and cultivate genuine collaboration.

Registration for this exclusive event is now open, with positions filling up quickly due to the limited number of 500 available spots. Early Bird rates are applicable only until April 18, 2025, making prompt registration highly advisable for those keen to partake in this unprecedented gathering of industry pioneers.

With its exciting new format and a sharp focus on connecting influential players within the biotechnology sphere, Advanced Therapies Europe 2025 seeks to set the bar high for future events, paving the way for the next wave of innovations in therapies that profoundly impact human health.